Literature DB >> 20398651

Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells.

Susan E Yanni1, Gary W McCollum, John S Penn.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity, reduce the production of retinal VEGF and neovascularization in relevant models of ocular disease. We hypothesized that COX-2 mediates VEGF production in retinal Müller cells, one of its primary sources in retinal neovascular disease. The purpose of this study was to determine the role of COX-2 and its products in VEGF expression and secretion. These studies have more clearly defined the role of COX-2 and COX-2-derived prostanoids in retinal angiogenesis. Müller cells derived from wild-type and COX-2 null mice were exposed to hypoxia for 0-24 h. COX-2 protein and activity were assessed by western blot analysis and GC-MS, respectively. VEGF production was assessed by ELISA. Wild-type mouse Müller cells were treated with vehicle (0.1% DMSO), 10 microM PGE(2), or PGE(2) + 5 microM H-89 (a PKA inhibitor), for 12 h. VEGF production was assessed by ELISA. Hypoxia significantly increased COX-2 protein (p < 0.05) and activity (p < 0.05), and VEGF production (p < 0.0003). COX-2 null Müller cells produced significantly less VEGF in response to hypoxia (p < 0.05). Of the prostanoids, PGE(2) was significantly increased by hypoxia (p < 0.02). Exogenous PGE(2) significantly increased VEGF production by Müller cells (p < 0.0039), and this effect was inhibited by H-89 (p < 0.055). These data demonstrate that hypoxia induces COX-2, prostanoid production, and VEGF synthesis in Müller cells, and that VEGF production is at least partially COX-2-dependent. Our study suggests that PGE(2), signaling through the EP(2) and/or EP(4) receptor and PKA, mediates the VEGF response of Müller cells. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20398651      PMCID: PMC2879458          DOI: 10.1016/j.exer.2010.03.019

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  62 in total

Review 1.  The role of cyclooxygenases in inflammation, cancer, and development.

Authors:  C S Williams; M Mann; R N DuBois
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

2.  Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.

Authors:  Ildiko Csiki; Kiyoshi Yanagisawa; Nobuhiro Haruki; Sorena Nadaf; Jason D Morrow; David H Johnson; David P Carbone
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model.

Authors:  Wenzheng Hu; Mark H Criswell; Anna Ottlecz; Tammy L Cornell; Ronald P Danis; George N Lambrou; Thomas A Ciulla
Journal:  Retina       Date:  2005-12       Impact factor: 4.256

4.  COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy.

Authors:  Lorna M Cryan; Graham P Pidgeon; Desmond J Fitzgerald; Colm J O'Brien
Journal:  Mol Vis       Date:  2006-04-20       Impact factor: 2.367

5.  Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium.

Authors:  A Bonazzi; V Mastyugin; P A Mieyal; M W Dunn; M Laniado-Schwartzman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

6.  Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.

Authors:  Aniruddha C Amrite; Surya P Ayalasomayajula; Narayan P S Cheruvu; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

7.  Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.

Authors:  Maen Abdelrahim; Stephen Safe
Journal:  Mol Pharmacol       Date:  2005-05-09       Impact factor: 4.436

8.  Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP.

Authors:  M M Höper; N F Voelkel; T O Bates; J D Allard; M Horan; D Shepherd; R M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  1997-12       Impact factor: 6.914

9.  Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites.

Authors:  Dawn Bradbury; Deborah Clarke; Claire Seedhouse; Lisa Corbett; Joanne Stocks; Alan Knox
Journal:  J Biol Chem       Date:  2005-06-21       Impact factor: 5.157

10.  The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.

Authors:  M Yamada; M Kawai; Y Kawai; Y Mashima
Journal:  Curr Eye Res       Date:  1999-10       Impact factor: 2.424

View more
  21 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Applications of azo-based probes for imaging retinal hypoxia.

Authors:  Md Imam Uddin; Stephanie M Evans; Jason R Craft; Lawrence J Marnett; Md Jashim Uddin; Ashwath Jayagopal
Journal:  ACS Med Chem Lett       Date:  2015-02-12       Impact factor: 4.345

3.  Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice.

Authors:  Kasra A Rezaei; Hassanain S Toma; Jiyang Cai; John S Penn; Paul Sternberg; Stephen J Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-03       Impact factor: 4.799

4.  Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy.

Authors:  Ningning Liu; Lei Chen; Na Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Authors:  Md Jashim Uddin; Chauca E Moore; Brenda C Crews; Cristina K Daniel; Kebreab Ghebreselasie; J Oliver McIntyre; Lawrence J Marnett; Ashwath Jayagopal
Journal:  J Biomed Opt       Date:  2016-09-01       Impact factor: 3.170

6.  Visualizing HIF-1α mRNA in a Subpopulation of Bone Marrow-Derived Cells to Predict Retinal Neovascularization.

Authors:  Md Imam Uddin; Tyler C Kilburn; Craig L Duvall; John S Penn
Journal:  ACS Chem Biol       Date:  2020-10-20       Impact factor: 5.100

7.  Role of aldose reductase in diabetes-induced retinal microglia activation.

Authors:  Kun-Che Chang; Biehuoy Shieh; J Mark Petrash
Journal:  Chem Biol Interact       Date:  2019-01-23       Impact factor: 5.192

8.  Mitigation of oxygen-induced retinopathy in α2β1 integrin-deficient mice.

Authors:  Aasakiran Madamanchi; Megan Capozzi; Ling Geng; Zhengzhi Li; Richard D Friedman; S Kent Dickeson; John S Penn; Mary M Zutter
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-10       Impact factor: 4.799

9.  Inflammation modulates expression of laminin in the central nervous system following ischemic injury.

Authors:  Kyungmin Ji; Stella E Tsirka
Journal:  J Neuroinflammation       Date:  2012-07-03       Impact factor: 8.322

10.  Per2 mutation recapitulates the vascular phenotype of diabetes in the retina and bone marrow.

Authors:  Ashay D Bhatwadekar; Yuanqing Yan; Xiaoping Qi; Jeffrey S Thinschmidt; Matthew B Neu; Sergio Li Calzi; Lynn C Shaw; James M Dominiguez; Julia V Busik; Choogon Lee; Michael E Boulton; Maria B Grant
Journal:  Diabetes       Date:  2012-11-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.